A PROSPECTIVE, RANDOMIZED, OPEN LABEL BLINDED END POINT (PROBE), CROSS-OVER STUDY TO COMPARE THE EFFECTS OF TELMISARTAN AND LOSARTAN ON METABOLIC PROFILE OF RENAL TRANSPLANT PATIENTS.

Trial Profile

A PROSPECTIVE, RANDOMIZED, OPEN LABEL BLINDED END POINT (PROBE), CROSS-OVER STUDY TO COMPARE THE EFFECTS OF TELMISARTAN AND LOSARTAN ON METABOLIC PROFILE OF RENAL TRANSPLANT PATIENTS.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2013

At a glance

  • Drugs Losartan (Primary) ; Telmisartan (Primary)
  • Indications Hypertension
  • Focus Therapeutic Use
  • Acronyms COSTANT
  • Most Recent Events

    • 22 Feb 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01224860).
    • 02 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top